Karyopharm EVP’s small tax-driven share sale

Karyopharm Therapeutics EVP & Chief Medical Officer Reshma Rangwala reported a small, non-discretionary sale of common stock tied to taxes on vested equity.

Rhea-AI Filing Summary

Karyopharm Therapeutics EVP & Chief Medical Officer Reshma Rangwala reported a small, non-discretionary sale of common stock tied to taxes on vested equity. On April 21, 2026, a broker-assisted sale of 449 shares of common stock was executed at $8.94 per share.

According to the disclosure, this trade was carried out under a durable automatic sale instruction plan adopted on April 4, 2022 and was used to satisfy withholding tax liability from the vesting of restricted stock units. After this transaction, Rangwala directly holds 56,290 shares of Karyopharm common stock.

Insider Trade Summary

Net Seller: 449 shares

Net Sell 1 txn

Insider Rangwala Reshma

Role EVP & Chief Medical Officer

Sold 449 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	449	$8.94	$4K

Holdings After Transaction: Common Stock — 56,290 shares (Direct)

Footnotes (1)

1. F1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

Key Figures

Shares sold: 449 shares Sale price: $8.94 per share Shares held after transaction: 56,290 shares +2 more

5 metrics

Shares sold 449 shares Open-market broker-assisted sale on April 21, 2026

Sale price $8.94 per share Price for common stock sold on April 21, 2026

Shares held after transaction 56,290 shares Direct ownership following reported sale

Plan adoption date April 4, 2022 Durable automatic sale instruction plan adoption

Net shares sold 449 shares Net-sell direction in transaction summary

Key Terms

durable automatic sale instruction plan, withholding tax liability, restricted stock units, broker-assisted sale

4 terms

durable automatic sale instruction plan financial

"This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022"

withholding tax liability financial

"represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting"

restricted stock units financial

"withholding tax liability incurred upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

broker-assisted sale financial

"represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Karyopharm (KPTI) executive Reshma Rangwala report in this Form 4?

Executive Reshma Rangwala reported a small broker-assisted sale of 449 Karyopharm common shares at $8.94 per share. The transaction was linked to tax withholding obligations arising from the vesting of restricted stock units, rather than a discretionary decision to sell shares.

How many Karyopharm (KPTI) shares did the EVP & Chief Medical Officer sell and at what price?

Reshma Rangwala sold 449 shares of Karyopharm common stock at $8.94 per share. The sale was executed on April 21, 2026 as a broker-assisted transaction designed to cover withholding tax liabilities tied to restricted stock unit vesting.

Why was the Karyopharm (KPTI) insider sale described as non-discretionary?

The sale was executed under a durable automatic sale instruction plan adopted on April 4, 2022. It specifically covered withholding tax liability from restricted stock unit vesting, and the filing notes the trade did not represent a discretionary decision by the reporting person to sell shares.

How many Karyopharm (KPTI) shares does Reshma Rangwala own after this transaction?

Following the tax-related sale, Reshma Rangwala directly holds 56,290 shares of Karyopharm common stock. This indicates the 449 shares sold represent a small portion of her total reported holdings, and the transaction was mainly to satisfy equity-related tax obligations.

What is the purpose of the durable automatic sale instruction plan mentioned for Karyopharm (KPTI)?

The durable automatic sale instruction plan, adopted on April 4, 2022, governs pre-arranged broker-assisted sales. In this case, it facilitated selling 449 shares to satisfy withholding tax liabilities triggered when restricted stock units vested, reducing the need for a discretionary trade decision by the executive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/22/2026 - 04:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rangwala Reshma

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MASSACHUSETTS 02459

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/21/2026		S(1)		449	D	$8.94	56,290	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Reshma Rangwala	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)